Navitor Pharmaceuticals launches with $23.5 million Series A financing for novel drug discovery

Navitor Pharmaceutical, a Cambridge, Massachusetts, USA, a new biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling, today announced a $23.5 million Series A financing.

Proceeds from the financing will be used to augment Navitor’s proprietary drug discovery platform and accelerate the development of a pipeline of novel drugs that target cellular nutrient signaling via the mTORC1 pathway to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. Investors in the Series A financing include Polaris Partners, Atlas Venture, Johnson & Johnson Development, SR One and The Longevity Fund.

“With a proprietary platform and a world-class scientific team, Navitor is uniquely positioned to target newly-discovered nutrient signaling mechanisms that drive protein synthesis and cellular growth. We are harnessing this approach to develop novel therapeutics to treat a wide range of chronic diseases and rare disorders,” said George Vlasuk, president and chief executive of Navitor.